{"id":6657,"date":"2020-05-07T12:22:41","date_gmt":"2020-05-07T09:22:41","guid":{"rendered":"https:\/\/ufuture.com\/?p=6657"},"modified":"2020-05-07T12:22:41","modified_gmt":"2020-05-07T09:22:41","slug":"clinical-trials-of-covid-19-will-be-conducted-in-five-ukrainian-hospitals","status":"publish","type":"post","link":"https:\/\/ufuture.com\/en\/clinical-trials-of-covid-19-will-be-conducted-in-five-ukrainian-hospitals\/","title":{"rendered":"Clinical trials of COVID-19 will be conducted in five Ukrainian hospitals"},"content":{"rendered":"<p><strong>Experts will analyze the action of the drug &#8220;Bioven&#8221; of the pharmaceutical company Biopharma, whose strategic investor is UFuture<\/strong><\/p>\n<p>On May 4, 2020, the Ministry of Health of Ukraine issued Order \u21161038 \u201cOn conducting a clinical trial of a medicinal product intended for the implementation of measures aimed at preventing the occurrence and spread, localization and elimination of coronavirus disease (COVID-19)\u201d.<\/p>\n<blockquote><p>\u201cBiopharma has received official approval to begin clinical trials of a drug potentially effective in the treatment of COVID-19. Optimal life-sustaining therapy for patients with severe pneumonia caused by a new strain of coronavirus will alleviate the course of the disease and reduce the hospital load,\u201d <cite>Kostyantyn Yefymenko, President of Biopharma, said.<\/cite><\/p><\/blockquote>\n<p>According to the document, studies to evaluate the effectiveness of the drug in the treatment of patients with pneumonia caused by SARS-CoV-2 will be conducted on the basis of:<\/p>\n<ul>\n<li>Kyiv City Clinical Hospital \u211617 (Department of Anesthesiology and Intensive Care);<\/li>\n<li>Bila Tserkva City Hospital \u21163 (Infectious department);<\/li>\n<li>Lviv Regional Infectious Diseases Clinical Hospital (Department of Resuscitation and Intensive Care);<\/li>\n<li>City Infectious Diseases Hospital of Odessa City Council (Infectious boxing department);<\/li>\n<li>Kyiv City Clinical Hospital \u21164 (Department of Anesthesiology and Intensive Care).<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Experts will analyze the action of the drug &#8220;Bioven&#8221; of the pharmaceutical company Biopharma, whose strategic investor is UFuture On&#8230;<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/posts\/6657"}],"collection":[{"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/comments?post=6657"}],"version-history":[{"count":1,"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/posts\/6657\/revisions"}],"predecessor-version":[{"id":6659,"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/posts\/6657\/revisions\/6659"}],"wp:attachment":[{"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/media?parent=6657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/categories?post=6657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ufuture.com\/en\/wp-json\/wp\/v2\/tags?post=6657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}